PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA

The U.S. Food and Drug Administration recently approved two poly‐adenosine diphosphate‐ribose polymerase (PARP) inhibitors, olaparib and rucaparib, for treatment of biomarker‐positive metastatic castrate resistant prostate cancer. The benefits of PARP inhibition have been well characterized in patie...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Risdon, Emily N., Chau, Cindy H., Price, Douglas K., Sartor, Oliver, Figg, William D.
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons, Inc. 2020
Sujets:
Genitourinary Cancer
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794174/
https://ncbi.nlm.nih.gov/pubmed/32790034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0697
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires